PDCD1 and osteosarcoma: However, combined treatment with the anti-PD-1 mAb and JQ-1 resulted in more pronounced tumor regression and ultimate cure in three-quarters (6/8) of the mice, exhibiting much better antitumor efficacy against osteosarcoma than either monotherapy alone (Fig. 6A, B, C).